Oppenheimer Initiates Coverage On Ligand Pharmaceuticals with Outperform Rating, Announces Price Target of $135
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer has initiated coverage on Ligand Pharmaceuticals with an Outperform rating and set a price target of $135.

October 03, 2024 | 12:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Oppenheimer has initiated coverage on Ligand Pharmaceuticals with an Outperform rating and a price target of $135, indicating a positive outlook.
The initiation of coverage with an Outperform rating and a specific price target of $135 by Oppenheimer suggests a positive outlook for Ligand Pharmaceuticals. This is likely to boost investor confidence and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100